{"protocolSection": {"identificationModule": {"nctId": "NCT00096954", "orgStudyIdInfo": {"id": "Q2982g"}, "organization": {"fullName": "Genentech, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)", "officialTitle": "A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)", "acronym": "EXACT"}, "statusModule": {"statusVerifiedDate": "2017-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-02", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2010-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2004-11-17", "studyFirstSubmitQcDate": "2004-11-17", "studyFirstPostDateStruct": {"date": "2004-11-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-08-08", "resultsFirstSubmitQcDate": "2011-11-03", "resultsFirstPostDateStruct": {"date": "2011-12-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-05-16", "lastUpdatePostDateStruct": {"date": "2017-06-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Genentech, Inc.", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This was a multicenter, parallel-group, double-blind, randomized, placebo-controlled study that enrolled 333 subjects. These subjects were 12-75 years old with atopic asthma, had elevated serum total Immunoglobulin E (IgE), had a baseline forced expiratory volume in 1 second (FEV1) \u2265 80% predicted, and were on inhaled corticosteroids with or without other controller asthma medications (e.g., long-acting \u03b22-agonists \\[LABAs\\], leukotriene receptor antagonist \\[LTRA\\], or immunotherapy)."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Omalizumab (Xolair)", "Atopic Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 333, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Omalizumab", "type": "EXPERIMENTAL", "description": "Omalizumab (Xolair) administered in this study was either a minimum of 0.008 mg/kg/IgE \\[IU/mL\\] every 2 weeks or a minimum of 0.016 mg/kg/IgE \\[IU/mL\\] every 4 weeks.", "interventionNames": ["Drug: omalizumab (Xolair)"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered in this study was either a minimum of 0.008 mg/kg/IgE \\[IU/mL\\] every 2 weeks or a minimum of 0.016 mg/kg/IgE \\[IU/mL\\] every 4 weeks.", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "omalizumab (Xolair)", "description": "Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \\> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.", "armGroupLabels": ["Omalizumab"]}, {"type": "DRUG", "name": "placebo", "description": "The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Rate of Asthma Exacerbations Over the 24 Week Treatment Period", "description": "A protocol-defined asthma exacerbation was a worsening of asthma requiring treatment with oral or intravenous corticosteroid burst and/or a doubling of the baseline inhaled corticosteroids (ICS) dose for at least 3 days.\n\nThe rate of protocol-defined asthma exacerbations, normalized by subject-time at risk and computed over the 24 week treatment period in each treatment group.", "timeFrame": "Start of treatment to 24 weeks"}], "secondaryOutcomes": [{"measure": "Number of Participants Experiencing One or More Protocol-defined Asthma Exacerbations During the Treatment Period", "description": "The number of patients reporting one or more protocol-defined asthma exacerbations during the 24 week treatment period. A protocol-defined asthma exacerbation was a worsening of asthma requiring treatment with oral or intravenous corticosteroid burst and/or a doubling of the baseline inhaled corticosteroids (ICS) dose for at least 3 days.", "timeFrame": "Start of treatment to 24 weeks"}, {"measure": "Change From Baseline in Nocturnal and Daytime Asthma Symptom Scores at Week 24", "description": "The daytime asthma symptom score assessed the symptoms: shortness of breath, chest discomfort, wheezing, and cough over the previous 24 hour period on a scale of 0(no symptoms) to 4(marked discomfort).\n\nThe nocturnal asthma score was the patient's response to:How did you sleep last night? rated on a scale of 0(no problems) to 4(difficulty sleeping;rescue medicine used).\n\nScores were collected daily. Change from Baseline (mean of last 28 days prior to first dosing date) at Week 24 (mean of last 28 days prior to week 24 visit).\n\nA negative change from baseline score indicates improvement.", "timeFrame": "Baseline and 24 weeks"}, {"measure": "Relative Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 24", "description": "Spirometry was used to assess FEV1. All spirometry measurements were performed in accordance with the American Thoracic Society (ATS) guidelines.\n\nThe relative percent change from baseline in forced expiratory volume (liters) in one second (FEV1) was calculated at week 24 using the formula: (FEV1 at week 24 - FEV1 at baseline) / FEV1 at baseline \\* 100 for each treatment group.", "timeFrame": "Baseline and 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have a documented history of asthma as well as evidence of \u2265 12% reversibility of FEV1. Evidence of \u2265 12% reversibility of FEV1 may be obtained by any one of the following measures: 1) Documentation of \u2265 12% reversibility of FEV1 after albuterol administration at any time during the preceding 24 months; 2) Documentation of \u2265 12% improvement in FEV1 with two separate measurements obtained within a 4-week period surrounding an asthma exacerbation during the preceding 24 months; 3) Demonstration of \u2265 12%reversibility of FEV1 after albuterol administration at the time of screening\n* Have baseline FEV1 \u2265 80% predicted normal value prior to randomization\n* Have a positive skin test (diameter of wheal \u2265 3 mm vs. control) or in vitro radioallergosorbent test (RAST(R)) or ImmunoCap(R) to one relevant perennial aeroallergen such as cat or house dust mites documented within the previous year\n* Be receiving at least an inhaled corticosteroid dosage of fluticasone dry powder inhaler (DPI) \u2265 200 ug/day or equivalent ex-valve dose during the 12 weeks prior to the screening visit\n* During the 4-week run-in period prior to randomization, demonstrate evidence of inadequate asthma symptom control despite inhaled corticosteroids with or without other controller asthma medications (e.g., LABA, LTRA, immunotherapy). Inadequate asthma symptom control is defined as at least one of the following reported on the subject diary card during the 4-week run-in period: Daytime asthma symptoms as a score of \u2265 1 (scale of 0-4) on at least 20 of 28 days (missing data to be treated as a day with no symptoms) and a mean symptom score of \u2265 1.5 (mean will be calculated based on only data supplied; missing values will not be considered) or Nighttime awakening because of asthma symptoms (more than 4 times during the 4-week run-in period)\n* Meet the study drug-dosing table eligibility criteria (serum baseline IgE level \u2265 30 to \u2264 1300 IU/mL and body weight \u2265 20 to \u2264 150 kg)\n* If a female of childbearing potential, use an effective method of contraception (in the opinion of the investigator) to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study\n\nExclusion Criteria:\n\n* Have received chronic systemic corticosteroids (oral or intravenous) within 3 months or have received a burst of oral corticosteroids within the last 2 weeks prior to screening\n* Have received Xolair therapy at any time within 12 months prior to screening\n* Are pregnant or lactating\n* Have a known hypersensitivity to any ingredients of Xolair, including excipients (sucrose, histidine, polysorbate 20)\n* Have a lifetime history of smoking \\> 10-pack years\n* Have active lung disease other than asthma (e.g., chronic bronchitis, emphysema, cystic fibrosis, chronic obstructive pulmonary disease)\n* Have a history of upper respiratory infection or lower respiratory infection within the 30 days prior to randomization\n* Have a diagnosis of aspirin or nonsteroidal anti-inflammatory drug-induced asthma\n* Have taken immunosuppressants or other investigational drugs within the 30 days prior to screening\n* Have a significant medical illness other than asthma", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Karin Rosen, MD, PhD", "affiliation": "Genentech, Inc.", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Omalizumab (Xolair)", "description": "Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \\> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site."}, {"id": "FG001", "title": "Placebo", "description": "The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "159"}, {"groupId": "FG001", "numSubjects": "174"}]}, {"type": "Received Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "157"}, {"groupId": "FG001", "numSubjects": "171"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "135"}, {"groupId": "FG001", "numSubjects": "154"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "20"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Sponsors Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Initiation of immunotherapy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "5"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Omalizumab (Xolair)", "description": "Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \\> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site."}, {"id": "BG001", "title": "Placebo", "description": "The dose of placebo was administered by subcutaneous injection every 2 or 4 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "157"}, {"groupId": "BG001", "value": "171"}, {"groupId": "BG002", "value": "328"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36.0", "spread": "14.7"}, {"groupId": "BG001", "value": "38.1", "spread": "15.1"}, {"groupId": "BG002", "value": "37.1", "spread": "14.9"}]}]}]}, {"title": "Sex: Female, Male", "description": "Baseline characteristic numbers reflect the number of participants who received at least one dose of drug. Two participants in the Xolair group and three participants in the placebo group were not dosed.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "110"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "226"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "102"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Rate of Asthma Exacerbations Over the 24 Week Treatment Period", "description": "A protocol-defined asthma exacerbation was a worsening of asthma requiring treatment with oral or intravenous corticosteroid burst and/or a doubling of the baseline inhaled corticosteroids (ICS) dose for at least 3 days.\n\nThe rate of protocol-defined asthma exacerbations, normalized by subject-time at risk and computed over the 24 week treatment period in each treatment group.", "populationDescription": "Modified Intent-to-Treat - All randomly assigned patients who received at least 1 dose of study drug (omalizumab or placebo).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "exacerbations per 24 patient-week period", "timeFrame": "Start of treatment to 24 weeks", "groups": [{"id": "OG000", "title": "Omalizumab (Xolair)", "description": "Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \\> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site."}, {"id": "OG001", "title": "Placebo", "description": "The dose of placebo was administered by subcutaneous injection every 2 or 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "171"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.205"}, {"groupId": "OG001", "value": "0.258"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Experiencing One or More Protocol-defined Asthma Exacerbations During the Treatment Period", "description": "The number of patients reporting one or more protocol-defined asthma exacerbations during the 24 week treatment period. A protocol-defined asthma exacerbation was a worsening of asthma requiring treatment with oral or intravenous corticosteroid burst and/or a doubling of the baseline inhaled corticosteroids (ICS) dose for at least 3 days.", "populationDescription": "Modified Intent-to-Treat - All randomly assigned patients who received at least 1 dose of study drug (omalizumab or placebo).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Start of treatment to 24 weeks", "groups": [{"id": "OG000", "title": "Omalizumab (Xolair)", "description": "Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \\> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site."}, {"id": "OG001", "title": "Placebo", "description": "The dose of placebo was administered by subcutaneous injection every 2 or 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "171"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "33"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Nocturnal and Daytime Asthma Symptom Scores at Week 24", "description": "The daytime asthma symptom score assessed the symptoms: shortness of breath, chest discomfort, wheezing, and cough over the previous 24 hour period on a scale of 0(no symptoms) to 4(marked discomfort).\n\nThe nocturnal asthma score was the patient's response to:How did you sleep last night? rated on a scale of 0(no problems) to 4(difficulty sleeping;rescue medicine used).\n\nScores were collected daily. Change from Baseline (mean of last 28 days prior to first dosing date) at Week 24 (mean of last 28 days prior to week 24 visit).\n\nA negative change from baseline score indicates improvement.", "populationDescription": "Modified Intent-to-Treat. Patients with missing Asthma Symptom Score data at week 24 were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Omalizumab (Xolair)", "description": "Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \\> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site."}, {"id": "OG001", "title": "Placebo", "description": "The dose of placebo was administered by subcutaneous injection every 2 or 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"title": "Daytime", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.73", "spread": "0.72"}, {"groupId": "OG001", "value": "-0.67", "spread": "0.72"}]}]}, {"title": "Nocturnal", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.48", "spread": "0.77"}, {"groupId": "OG001", "value": "-0.49", "spread": "0.67"}]}]}]}, {"type": "SECONDARY", "title": "Relative Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 24", "description": "Spirometry was used to assess FEV1. All spirometry measurements were performed in accordance with the American Thoracic Society (ATS) guidelines.\n\nThe relative percent change from baseline in forced expiratory volume (liters) in one second (FEV1) was calculated at week 24 using the formula: (FEV1 at week 24 - FEV1 at baseline) / FEV1 at baseline \\* 100 for each treatment group.", "populationDescription": "Modified Intent-to-Treat. Patients with missing FEV1 data at either baseline or week 24 were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Omalizumab (Xolair)", "description": "Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \\> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site."}, {"id": "OG001", "title": "Placebo", "description": "The dose of placebo was administered by subcutaneous injection every 2 or 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.15", "spread": "21.53", "lowerLimit": "1.23", "upperLimit": "8.39"}, {"groupId": "OG001", "value": "-0.75", "spread": "11.90", "lowerLimit": "1.23", "upperLimit": "8.39"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first dosing date to 30 days after last dosing date, or the last day on study, whichever is earlier. (Up to 29.3 weeks)", "eventGroups": [{"id": "EG000", "title": "Omalizumab (Xolair)", "description": "Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \\> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.", "seriousNumAffected": 4, "seriousNumAtRisk": 157, "otherNumAffected": 36, "otherNumAtRisk": 157}, {"id": "EG001", "title": "Placebo", "description": "The dose of placebo was administered by subcutaneous injection every 2 or 4 weeks.", "seriousNumAffected": 6, "seriousNumAtRisk": 171, "otherNumAffected": 56, "otherNumAtRisk": 171}], "seriousEvents": [{"term": "Esophageal perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Hyperglycemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Diffuse large B-cell lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 171}]}, {"term": "Dyspnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Abortion induced", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 171}]}], "otherEvents": [{"term": "upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 171}]}, {"term": "sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 171}]}, {"term": "nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 171}]}, {"term": "headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 171}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "This is a stand-alone study to fulfill one of the post-marketing commitments."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."}, "pointOfContact": {"title": "Medical Communications", "organization": "Hoffman-LaRoche", "phone": "800-821-8590"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "T8", "name": "Histidine", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AA", "name": "Amino Acids"}]}}, "hasResults": true}